A U.S. Patent for “Monoclonal Antibodies that Specifically Block Biological Activity of a Tumor Antigen” was awarded to Eisai on December 17th, 2019. The present invention relates to purified novel monoclonal antibodies that specifically bind to the alpha-folate receptor and compositions thereof. In some embodiments, the antibodies of the invention block the biological activity of FR-.alpha.. The antibodies and compositions of the invention are useful in the treatment of certain cancers, particularly cancers that have increased cell surface expression of the alpha-folate receptor… Learn More